Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics

KKRX:323990
3,685.00
KRW
-120.00
(-3.15%)
-644.75EPS
118.42BMarket Cap

Total Valuation

KRW

As of June 30, 2026, Vaxcell-Bio Therapeutics carries a market capitalization of 118.42B, placing it among publicly traded companies globally. Its enterprise value stands at 104.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap118.42B
Enterprise Value104.77B

Share Statistics

As of June 30, 2026, Vaxcell-Bio Therapeutics has 23.17M shares outstanding.

Shares Outstanding23.17M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 18.16, and the price-to-book ratio stands at 2.22.

PS Ratio18.16
PB Ratio2.22
P/TBV Ratio2.56
P/FCF Ratio-6.50
P/OCF Ratio-11.14

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 16.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 104.77B versus a market cap of 118.42B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales16.09

Financial Position

As of June 30, 2026, Vaxcell-Bio Therapeutics maintains a current ratio of 5.56, meaning it holds 5.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.92, indicating elevated leverage, while an interest coverage ratio of -72.52 demonstrates limited ability to service its debt obligations.

Current Ratio5.56
Quick Ratio4.34
Debt / Equity2.92
Debt / EBITDA-0.11
Interest Coverage-72.52

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, Vaxcell-Bio Therapeutics posted a negative return on equity (ROE) of -24.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -22.69, reflecting losses generated across the asset base. The company generates approximately 73.57M in revenue per employee across its workforce of 88.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 17.21 indicates how many times Vaxcell-Bio Therapeutics sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-24.64
Return on Assets (ROA)-22.69
Revenue Per Employee73.57M
Employee Count88.50
Inventory Turnover17.21

Stock Price Statistics

KRW

As of the close on November 17, 2026, Vaxcell-Bio Therapeutics's stock has declined approximately 62.89% over the past 52 weeks. The 50-day moving average sits at 4,195.20, while the 200-day moving average is 5,936.50.

52-Week Price Change-62.89%
50-Day Moving Average4,195.20
200-Day Moving Average5,936.50

Income Statement

KRW

Over the twelve months ended June 30, 2026, Vaxcell-Bio Therapeutics generated 6.51B in revenue and converted that into -14.92B in net income, yielding earnings per share of -644.75. EBITDA reached -14.35B, while operating income came in at -16.73B.

Revenue6.51B
Gross Profit485.43M
Operating Income-16.73B
Pretax Income-14.92B
Net Income-14.92B
EBITDA-14.35B
EBIT-16.74B
Earnings Per Share (EPS)-644.75

Balance Sheet

KRW

As of June 30, 2026, Vaxcell-Bio Therapeutics holds 15.21B in cash and equivalents against 1.56B in total debt, resulting in a net debt position of -5.57B. Total book value stands at 53.27B, with working capital of 16.01B providing operational flexibility.

Cash & Cash Equivalents15.21B
Total Debt1.56B
Net Debt-5.57B
Equity (Book Value)53.27B
Book Value Per Share2,298.92
Working Capital16.01B

Cash Flow

KRW

Vaxcell-Bio Therapeutics produced -10.61B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.58B in capital expenditures, free cash flow totaled -18.20B - equivalent to -786.56 per share.

Operating Cash Flow-10.61B
Capital Expenditures-7.58B
Free Cash Flow-18.20B
FCF Per Share-786.56

Margins

Over the twelve months ended June 30, 2026, Vaxcell-Bio Therapeutics posted a gross margin of 7.46, reflecting its pricing power and cost economics. The operating margin of -256.88 and net profit margin of -229.11 provide insight into operational efficiency.

Gross Margin7.46
Operating Margin-256.88
Pretax Margin-229.11
Profit Margin-229.11
EBITDA Margin-220.37

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vaxcell-Bio Therapeutics shareholders.

Shareholder Yield0.80
FCF Yield-15.39

Stock Splits

Vaxcell-Bio Therapeutics's most recent stock split took place on November 10, 2023 with a 5:6 split ratio.

Last Split Date11/10/2023
Split Ratio5:6

Scores

As of June 30, 2026, Vaxcell-Bio Therapeutics has an Altman Z-Score of 10.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score10.52